Germany has at present voted to ban medical hashish flower from its statutory medical health insurance scheme, in a controversial transfer critics say could have an outsized influence on the ‘significantly in poor health’.
Provisions embedded in a broad medical health insurance financial savings bundle, the GKV-Beitragssatzstabilisierungsgesetz, handed by way of the Bundestag at present (July 10) will imply medical hashish flower is now not reimbursed, whereas sufferers searching for extract cowl should first bear a compulsory six-month course of an accredited cannabis-based completed drugs.
Handed with the purpose of saving prices for insurers, trade associations and medical professionals say it’s going to finally increase prices, whereas leaving sufferers mid-treatment with out safety, and sure pushing many again to the illicit market.
Writing on LinkedIn, Dr Christiane Neubaur, Managing Director of the Verband der Hashish versorgenden Apotheken (VCA), mentioned: “Many sufferers who obtain hashish prescription medicines at present don’t fall into these accredited indications. A blanket six-month precedence for completed medicinal merchandise can due to this fact create appreciable entry boundaries if there is no such thing as a suitably authorised completed medicinal product for the precise indication.”
What occurred?
The GKV-Beitragssatzstabilisierungsgesetz is primarily a broad financial savings bundle for Germany’s statutory medical health insurance system, the GKV, which covers roughly 90% of the inhabitants. Hashish seems in a single clause, the modification to §31 Abs. 6 of the Social Code Ebook V (SGB V), which defines what the GKV should reimburse.
The earlier model of that provision gave sufferers with a severe sickness the correct to hashish within the type of each flowers and extracts, in addition to the pharmaceutical elements dronabinol and nabilon, topic to circumstances. The brand new §31(6) merely removes flowers. There isn’t a substitute provision and no transition association for sufferers already in secure therapy.
What does stay, specifically extracts and dronabinol, has now additionally turn into tougher for sufferers to entry. The amended provision states that earlier than any extract declare is legitimate underneath GKV, the treating doctor should first prescribe an accredited cannabis-containing completed drugs for a six-month therapeutic trial.
Provided that that trial is accomplished, or if the statutory circumstances for bypass are met, can a affected person entry extract reimbursement. The circumstances for entitlement are in any other case unchanged. Sufferers will need to have a severe sickness the place commonplace therapy is unavailable or unsuitable, and there should be a significant prospect of profit.
The six-month gateway was not a part of the federal government’s unique invoice. The cupboard draft (BT-Drucksache 21/6130) eliminated flowers however mentioned nothing a few finished-medicine priority rule. That provision appeared in a coalition Änderungsantrag, an modification tabled by the governing events within the Gesundheitsausschuss, and was included into the committee’s remaining suggestion (BT-Drucksache 21/7016) on 8 July, two days earlier than the Bundestag vote.
The 4 completed medicines in opposition to which the six-month trial should be run are presently:
- Sativex, accredited for spasticity in a number of sclerosis
- Epidyolex, accredited for sure extreme types of epilepsy
- Canemes, accredited for chemotherapy-related nausea and vomiting
- Exilby, a full-spectrum extract developed by Vertanical and accredited in June 2026 for power again ache, although nonetheless in value negotiations with the Federal Joint Committee and never but listed on the reimbursed market.
Prescribing any of these 4 merchandise outdoors their accredited indication constitutes an off-label use, requiring separate medical justification and particular person GKV approval. For almost all of hashish sufferers, whose circumstances don’t match these 4 particular labels, the sensible path to compliant reimbursement underneath the brand new guidelines runs by way of a compulsory trial of a medication they don’t seem to be technically accredited for.
READ MORE…
A financial savings legislation that will price extra
Trade opposition was swift and focused the coverage’s financial logic immediately. Michael Greif, Managing Director of the Bundesverband Hashish Wirtschaft (BvCW), mentioned the reform ‘fully misses its precise goal.’
“The prices for well being insurers will doubtless rise fairly than fall, as a result of particular person compounded preparations are sometimes extra economical than costly completed medicines. On the similar time, physicians’ therapeutic autonomy within the medical hashish area is massively curtailed,” he defined.
The BfArM’s nationwide survey of GKV hashish prescriptions discovered that 76.4% of sufferers cited power ache as their major situation, a cohort for whom solely Exilby carries an accredited indication, and that drug is just not but on the reimbursed market.
Most of these sufferers would face a compulsory trial of a product prescribed off-label, a route requiring separate medical justification and particular person GKV approval, and sometimes increased price.
Kathrin Konyen, Medical Hashish Sector Lead on the BvCW, mentioned the absence of any transition safety for sufferers already mid-treatment deepens the priority: “A blanket precedence for completed medicines forces medical doctors into inflexible remedy schemes, creates further forms and endangers therapy success.
“Remedy choices should be oriented to particular person medical wants – not blanket necessities. A precedence would solely be medically wise if, for the precise sickness, an accredited and out there preparation exists and no medical objections apply.”
GKV expenditure on medical hashish totalled roughly €205 million in 2025, protecting flowers and extracts mixed, in keeping with GKV Gamsi quarterly information cited by the BvCW. That determine sits in opposition to a projected structural GKV funding hole of as much as €40 billion by 2030, making hashish a marginal line within the financial savings calculus, whereas risking price substitution upwards by way of higher-priced completed medicines.
Antonia Menzel, Chairwoman of the Bundesverband pharmazeutischer Cannabinoidunternehmen (BPC), instructed Krautinvest the arithmetic doesn’t help the said aim. “This modification doesn’t save a single euro; quite the opposite. It forces medical doctors to prescribe preparations for six months that may be costlier per therapy month than the tried-and-tested components and are usually not even accredited for many medical circumstances. That is fully misplaced in a legislation supposed to stabilise contribution charges.”
What occurs subsequent
The laws doesn’t require Bundesrat consent to take impact, it’s categorized as nicht zustimmungspflichtig. Germany’s higher chamber can, nevertheless, refer it to a mediation committee (Vermittlungsausschuss), a course of that might delay implementation and reopen the hashish provisions for revision.
The BvCW has written to the Länder urging them to take that route, with three particular calls for. These embrace abolition or vital shortening of the six-month obligatory trial, statutory exemption clauses protecting contraindications, intolerances, and unsuitable dosage kinds, and a authorized transition association for sufferers presently in established hashish therapies.
The end result of Vertanical’s ongoing value negotiations with the Federal Joint Committee will even be carefully watched. Till a reimbursed value for Exilby is agreed, the accredited gateway for almost all of power ache sufferers, the biggest single prognosis cohort, stays open in legislation however closed in observe.
